Anti-Therapeutic Action: flashbacks

Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences

mycolabadmin

People who use psychedelic substances like psilocybin or LSD sometimes experience profound changes in how they understand reality that can be distressing and last for months or years. This study interviewed 26 people who went through such difficult experiences and found that what helped them most was practicing grounding techniques (like yoga, spending time in nature, and creative activities), talking about their experiences with others, and learning to accept their new perspectives. The research shows that while these experiences can be challenging, people can recover and grow from them with the right support and practices.

Read More »

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Read More »

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

mycolabadmin

This comprehensive review examines how scientists use advanced imaging techniques like PET and SPECT scans to study how hallucinogenic drugs such as LSD and psilocybin interact with the brain. The research shows these drugs primarily bind to serotonin receptors, particularly the 5-HT2A subtype, which appear responsible for producing hallucinations. While scientific understanding of hallucinogen mechanisms has advanced significantly, there is still much to learn about their complete effects on brain chemistry and their potential therapeutic applications.

Read More »

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

mycolabadmin

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Read More »

Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study

mycolabadmin

This study examined how childhood trauma can resurface during psychedelic experiences and what happens afterward. Researchers surveyed over 600 people who had difficult experiences after using psychedelics, and interviewed 18 of them in detail. They found that trauma surfaced in different ways—some people vividly relived events, others felt intense bodily sensations, and some experienced confusion. About half of participants found healing from the experience, while others struggled with ongoing trauma symptoms or mixed outcomes. The research emphasizes the importance of proper preparation, supportive settings, and follow-up integration work to help people process these experiences safely.

Read More »
Scroll to Top